How Long Semaglutide Stays in Your System — and What Happens After Your Last Dose

The pharmacokinetics: what the STEP trial programme established about clearance

The STEP 1 trial, published in the New England Journal of Medicine, followed adults using 2.4mg semaglutide weekly over 68 weeks and documented not just weight outcomes but the drug's pharmacological profile. Semaglutide binds strongly to albumin in the blood, that albumin binding is precisely why it has such a long half-life compared with older GLP-1 medicines. The practical upshot: a single missed injection doesn't flush the medicine from your body in days the way a short-acting drug might; concentrations fall gradually over several weeks.

After the final dose, semaglutide concentration halves roughly every seven days, and if you want to understand when Wegovy peaks in your system before that decline begins, the detail is worth reading before drawing conclusions about timing. That figure sits in the prescribing information, and it's the reason NHS guidance uses a five-week reference point for situations where full clearance matters, conception planning being the clearest example. It is worth knowing that "out of the system" and "no longer having any effect" are not quite the same thing: appetite-suppressing effects may ease before full clearance, and conversely some GI sensitivity can linger a little beyond what the numbers alone would predict.

If you want to understand how the drug accumulates during active treatment before that clearance phase begins, the detail is covered in our page on how Wegovy builds up in your system.

What stopping means for weight (the evidence is sobering

A question our prescribers hear most weeks is some version of: "If I stop, do I just keep the weight off?" The honest answer, grounded in the trial data, is that for most people the answer is no) at least not without significant ongoing intervention.

The STEP 1 extension study followed participants for one year after stopping semaglutide and found that, on average, roughly two-thirds of weight lost during treatment was regained within twelve months. The NHS patient information on semaglutide is clear that weight management medicines work alongside dietary and activity changes, not instead of them, and that stopping without a plan tends to erode results. This isn't a failure of the medicine; it reflects the biology of appetite regulation. GLP-1 receptors that were being continuously stimulated return to baseline signalling, hunger hormones rebound, and energy intake typically rises again.

That's why the decision to stop is treated clinically, not commercially. NICE's recommendation for semaglutide (TA875) includes a review point after six months on the maintenance dose, and the question of whether to continue, switch or stop is built into the prescribing framework. Stopping abruptly for a non-clinical reason, without a conversation with your prescriber, means losing that structured review.

Surgery, conception and other situations where clearance timing is clinically specific

There are a handful of situations where knowing semaglutide's approximate clearance window has real clinical weight rather than being background curiosity.

Surgery is the most time-sensitive. Because GLP-1 medicines slow gastric emptying, there's a risk that stomach contents remain present under general anaesthesia even after a standard fasting period. NHS England's guidance on weight-management injections advises patients to tell their surgical and anaesthetic team they are taking a GLP-1 medicine well in advance of any procedure. Some teams are now requesting a pause of several weeks before elective surgery, and our page on how to flush semaglutide out of your system explains what that clearance process actually involves and what you can do to support it.

For conception planning, the MHRA advises using reliable contraception throughout treatment. Women taking oral contraceptives alongside tirzepatide specifically should add a non-oral method during the first four weeks of treatment and for four weeks after each dose increase; this interaction evidence is less established for semaglutide, but the contraception advice remains. A washout period before trying to conceive is recommended, your prescriber will advise on timing. Semaglutide is not recommended during pregnancy or while breastfeeding.

There's also the question of whether stopping affects immune function, and our page on how semaglutide interacts with the immune system gives useful context alongside the evidence covered in our page looking at whether semaglutide lowers your immune system, given how limited and sometimes misrepresented it can be.

How to approach stopping, and what comes next

Semaglutide doesn't require a medically supervised taper the way some medicines do, but that's different from saying stopping is consequence-free or should happen without a clinical conversation. If your weight-management goals are met, if you're experiencing side effects that aren't settling, or if circumstances have changed, the right first step is a conversation with your prescriber rather than simply not ordering your next supply.

Some people find that revisiting the lifestyle foundations built during treatment (portion habits, protein intake, activity patterns) provides a buffer against rapid regain. Others move to a lower maintenance dose for a period. None of those decisions sit outside clinical oversight, and none should be made based on what felt right when stopping a supplement.

If you're considering semaglutide for the first time and want to understand the full picture before starting, the overview on Wegovy covers the licensed indications, the dosing schedule and what clinical support looks like in practice. For anyone weighing up injectable versus oral formats, our weight-loss treatment overview sets out the options clearly. When you're ready to talk to a prescriber, checking your eligibility is the right place to start, there's no charge for the consultation.